PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer	PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer	PD-L1 overexpression + FGFR3 amplification	Non Small Cell Lung Cancer	nivolumab + anlotinib Sensitive: C4 – Case Studies nivolumab + anlotinib Sensitive : C4	nivolumab + anlotinib Sensitive: C4 – Case Studies nivolumab + anlotinib Sensitive : C4

PD-L1 overexpression + FGFR3 amplification

Associations